Thalidomide-NH-CBP/p300 ligand 2 is primarily used in targeted protein degradation research. It functions as a bifunctional molecule, combining a thalidomide derivative with a ligand specific to CBP/p300 proteins. This design allows it to recruit the E3 ubiquitin ligase machinery to CBP/p300, marking these proteins for proteasomal degradation. Its application is significant in studying epigenetic regulation, as CBP/p300 are key transcriptional coactivators involved in gene expression modulation. Researchers utilize this compound to explore the roles of CBP/p300 in diseases like cancer, where these proteins are often dysregulated. Additionally, it serves as a tool for probing the therapeutic potential of selectively degrading CBP/p300 in pathological conditions.